FANCELLI, SARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 277
NA - Nord America 273
AS - Asia 52
AF - Africa 1
Totale 603
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 273
IE - Irlanda 73
IT - Italia 63
PL - Polonia 54
SE - Svezia 39
JO - Giordania 29
AT - Austria 28
HK - Hong Kong 14
GB - Regno Unito 5
CH - Svizzera 4
DE - Germania 3
NO - Norvegia 3
SG - Singapore 3
BE - Belgio 2
CN - Cina 2
FR - Francia 2
IN - India 2
VN - Vietnam 2
EG - Egitto 1
UA - Ucraina 1
Totale 603
Salva come PNG Salva come JPEG
Città #
Dublin 73
Warsaw 52
Chandler 40
Fairfield 30
Ashburn 24
Vienna 23
Woodbridge 17
Cambridge 14
Altamura 13
Lawrence 12
Florence 10
Houston 10
Wilmington 10
Seattle 9
Milan 6
Princeton 6
Boston 5
Bern 4
London 4
Andover 3
Ann Arbor 3
Hillsboro 3
Norwalk 3
Oslo 3
Recanati 3
San Diego 3
Anguillara Sabazia 2
Beijing 2
Bremen 2
Brussels 2
Chennai 2
Dong Ket 2
Falls Church 2
Livorno 2
Paris 2
Rufina 2
Acerra 1
Ancona 1
Bagno A Ripoli 1
Bari 1
Boardman 1
Buffalo 1
Chicago 1
Krefeld 1
Marcallo con Casone 1
Medford 1
New Bedfont 1
Padova 1
Phoenix 1
Verona 1
Washington 1
Totale 418
Salva come PNG Salva come JPEG
Nome #
A case report of eyelid Merkel cell carcinoma occurring under treatment with nivolumab for a lung adenocarcinoma. 146
TAS-102 in gastric cancer: Development and perspectives of a new biochemically modulated fluroropyrimidine drug combination 53
Defining the Ideal Patient with Hepatocellular Carcinoma for Second-Line Treatment 53
Italian survey of second tumors in patients with diagnosis of GIST (gastrointestinal stromal tumor) 52
Chasing the target: New phenomena of resistance to novel selective ret inhibitors in lung cancer. updated evidence and future perspectives 48
Results of the observational prospective RealFLOT study 41
REBECA trial: A new piece of the evidence for bevacizumab in platinum-resistant recurrent ovarian cancer 41
Absolute eosinophil count predicts clinical outcomes and toxicity in non-small cell lung cancer patients treated with immunotherapy 27
Alteration of the Nucleotide Excision Repair (NER) Pathway in Soft Tissue Sarcoma 24
Gender matters. Sex-related differences in immunotherapy outcome in patients with non-small cell lung cancer 21
Safety of Immune Checkpoint Inhibitors in Elderly Patients: An Observational Study 17
Challenges in the treatment of small cell lung cancer in the era of immunotherapy and molecular classification 16
Ivosidenib in IDH1-mutated cholangiocarcinoma: Clinical evaluation and future directions 16
Immune checkpoint blockade with anti-programmed cell death 1 (PD-1) monoclonal antibody (mAb) cemiplimab: ongoing and future perspectives in rare genital cancers treatment 15
Liquid Biopsy and Non-small-cell Lung Cancer: Expecting More Fluid Management of Patients 14
KRAS G12 isoforms exert influence over up-front treatments: A retrospective, multicenter, Italian analysis of the impact of first-line immune checkpoint inhibitors in an NSCLC real-life population 13
Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario 11
Mutations matter: An observational study of the prognostic and predictive value of KRAS mutations in metastatic colorectal cancer 11
Perioperative Tailored Treatments for Gastric Cancer: Times Are Changing 8
Perioperative Tailored Treatments for Gastric Cancer: Times Are Changing 7
Long-term response of more than 9 years to regorafenib in a heavily pretreated patient with metastatic colorectal cancer 3
null 3
Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study 2
Totale 642
Salva come PNG Salva come JPEG
Categoria #
all - tutte 3.243
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.243
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201916 0 0 0 0 3 1 0 0 0 2 5 5
2019/202065 4 3 4 3 9 6 6 6 6 5 9 4
2020/202196 5 9 0 30 4 3 3 9 8 8 5 12
2021/202237 0 2 3 0 0 4 4 4 1 3 3 13
2022/2023331 10 36 7 27 14 53 61 45 45 8 14 11
2023/202497 13 15 24 21 24 0 0 0 0 0 0 0
Totale 642